Modern concepts about pathogenesis of the tension-type headache and mechanisms of development of the tension-type headache and arterial hypertension phenotype

The aim of this review was to analyze domestic and foreign publications reflecting the main existing theories of tension-type headache (TTH) development and the search for common pathogenetic links of TTH with arterial hypertension (AH) as potential triggers for the development of the clinical TTH and AH phenotype.

Methods. We searched for articles in databases (eLibrary.ru, Web of Science, Scopus, PubMed, Clinical Case) by keywords. Search depth – 2006–2021.

Results. The analysis allowed us to identify the leading theories underlying the development of TTH: psychogenic, vascular, myofascial, biochemical and neurogenic. At the same time, a neurobiological theory has been considered: it combines some of the mechanisms of previously studied pathogenetic theories of TTH. In addition, there are the most important (from the clinical point of view) mechanisms of the comorbidity of TTH and AH, which underlie the development of the TTH + AH phenotype. In terms of these mechanisms, in recent years, it is of scientific interest to study the role of nitric oxide (NO) and NO-synthases, since they play an important role not only in the development of the comorbidity of two diseases simultaneously existing in one patient (phenotype «TTH and AH», but also in modulating the response to drugs for the treatment of TTH and AH. Modulators of NO and NO-synthases, which have been developed in recent years, can improve the efficacy and safety of therapy for this phenotype.

Conclusion. New approaches to predicting and disease-modifying therapy of the TTH and AH phenotype can increase the efficiency and safety of treatment, and improve the quality of life of patients, and reduce the risk of cardiovascular complications.

1. Yakhno N.N., Parfenov V.A., Alekseev V.V. Headache. M.: Remedium, 2000:150 p. (In Russian)

2. Medvedeva L.A., Zagorulko O. I., Gnezdilov A.V. The prevalence of headache among patients of a specialized pain clinic. Russian Journal of Pain (Rossiiskyi zhurnal boli). 2013;1(38):25–26. (In Russian). https://elibrary.ru/item.asp?id=20284891& Accessed May 11, 2021.

3. Chowdhury D. Tension type headache. Annals of Indian Academy of Neurology. 2012;15(1):83–88. https://pubmed.ncbi.nlm.nih.gov/23024570/

4. Oganov R.G., Timofeeva T.N., Koltunov I.E., Konstantinov V.V., Balanova Yu.A., Kapustina A.V. et al. Arterial hypertension epidemiology in Russia; the results of 2003–2010 Federal monitoring. Cardiovascular therapy and prevention (Kardiovaskulyarnaya terapiya i profi laktika). 2011;10(1):9–13. (In Russian). https://cardiovascular.elpub.ru/jour/article/view/1436. Accessed May 10, 2021.

5. Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S. et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specifi c associations in 1·25 million people The Lancet. 2014;383(9932):1899–1911. https://doi.org/10.1016/S0140-6736(14)60685-1

6. Prudenzano M.P., Monetti C., Merico L., Cardinali V., Genco S., Lamberti P., Livrea P. The comorbidity of migraine and hypertension. A study in a tertiary care headache centre. The Journal of Headache and Pain. 2005;6(4):220–222. https://doi.org/10.1007/s10194-005-0190-1

7. Pietrini U., De Luca M., De Santis G. Hypertension in headache patients? A clinical study. Acta Neurologica Scandinavica. 2005;112(4):259–264. https://doi.org/10.1111/j.1600-0404.2005.00476.x

8. Tokar’ O.O., Zhmereneckij K.V., Zadneprovskaya V.V., Nevrycheva E.V. Evaluation of extracranial and intracranial arterial blood flow in young patients with arterial hypertension associated with migraine or tension-type headache. Far Eastern Medical Journal (Dal’nevostochnyj medicinskij zhurnal). 2020;1:28–36. (In Russian). https://doi.org/10.35177/1994-5191-2020-1-28-36

9. Parfenov V.A., Ostroumova T.M., Ostroumova O.D., Pavleeva E.E. Features of the clinical picture in middle-aged patients with essential arterial hypertension. Therapeutic archive (Terapevticheskij arhiv). 2018;9:15–26. (In Russian). https://doi.org/10.26442/terarkh201890915-26

10. Parfenov V.A., Alekseev V.V., Shvareva N.S., Ryzhak A.A. Headache in patients with arterial hypertension. Clinical Gerontology (Klinicheskaya gerontologiya). 2001;6(5):3–9. (In Russian). https://cyberleninka.ru/article/n/golovnye-boli-u-patsientov-s-arterialnoy-gipertenziey-i-gipertonicheskimi-krizami/viewer. Accessed August 9, 2021].

11. Shnayder N.A., Petrova M.M., Moskaleva P.V., Shesternya P.A., Pozhilenkova E.A., Nasyrova R.F. The Role of Single-Nucleotide Variants of NOS1, NOS2, and NOS3 Genes in the Comorbidity of Arterial Hypertension and Tension-Type Headache. Molecules. 2021;26(1556):1–15. https://doi.org/10.3390/molecules26061556

12. Petrova M.M., Moskaleva P.V., Shnayder N.A., Nasyrova R.F. Comorbidity of arterial hypertension and tension-type headache. Cardiology (Kardiologiya). 2020;60(10):132–140. (In Russian). https://doi.org/10.18087/cardio.2020.10.n1363

13. Olesen J. New international headache classifi cation. Neuroepidemiology. 1989;8(2):53–55. https://doi.org/10.1159/000110166

14. Olesen J., Steiner T.J. The International classifi cation of headache disorders. 2nd ed. (ICDH-II). J. Neurology, Neurosurgery, and Psychiatry. 2004;75(6):808–811. http://dx.doi.org/10.1136/jnnp.2003.031286

15. ICHD-3. Headache Classifi cation Committee of the International Headache Society (IHS) The International Classifi cation of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202

16. Moskaleva P.V., Shnajder N.A., Petrova M.M., Nasyrova R.F. Scales and questionnaires for diagnosing tension headaches. Russian Journal of Pain (Rossijskij zhurnal boli). 2020;18(4):8–18. (In Russian). http://doi.org.10.17116/pain2020180418

17. Osipova V.V. Pericranial muscle dysfunction in primary headache and its correction. Neurology, neuropsychiatry, psychosomatics (Nevrologiya, nejropsixiatriya, psixosomatika). 2011;4:29–35. (In Russian). https://cyberleninka.ru/article/n/disfunktsiya-perikranialnyh-myshts-pri-pervichnoy-golovnoyboli-i-ee-korrektsiya Accessed May 11, 2021.

18. Belimova L.N., Balyazin V.A. The pathophysiological basis of tension-type headache. Kuban Scientific Medical Bulletin (Kubanskij nauchnyj medicinskij vestnik). 2016;5(160):139–147. (In Russian). https://www.elibrary.ru/item.asp?id=28303100 Accessed May 11, 2021.

19. Sorokina N.D., Percov S.S., Selickii G.V. Neurobiological mechanisms of tension headache and migraine: similarities and differences. Russian Journal of Pain (Rossiiskii zhurnal boli). 2018;3(57):96–108. (In Russian). https://doi.org/10.23888/PAVLOVJ2018263417-429

20. Medvedeva L.A., Zagorulko O.I., Shevczova G.E. The severity of anxiety-depressive spectrum disorders in patients with chronic headache. Anesthesiology and resuscitation (Anesteziologiya i reanimatologiya). 2016;61(5S):67. (In Russian). https://www.elibrary.ru/item.asp?id=27486262 Accessed May 10, 2021.

21. Janke E.A., Holroyd K.A., Romanek K. Depression increases onset of tension-type headache following laboratory stress. Pain. 2014;111(3):230–238. https://doi.org/10.1016/j.pain.2004.06.007

22. Kalashnikov V.I., Evtushenko S.K. Clinical and Doppler comparisons in patients with tension-type headache. International Neurological Journal (Mezhdunarodnyj nevrologicheskij zhurnal). 2016;80(2):71–79. (In Russian). https://www.elibrary.ru/item.asp?id=26330977 Accessed May 11, 2021.

23. Veyn A.M. Pain syndromes in neurological practice. M.: MEDpress-inform. 2001:368 p. (In Russian).

24. Alexeev V.V., Shechter A.I., Scorobogatich K.V., Shashkova E.V. Headaches with intracranial venous dysfunction. Pain (Bol’). 2008;3(20):15–21. (In Russian). https://painrussia.ru/upload/iblock/49f/49f7e392cb68b69f11501cbb3bfd4733.pdf Accessed August 9, 2021.

25. Tokar O.O., Zhmerenetsky K.V. Primary headaches in patients with arterial hypertension, mechanisms of their development, chronizationand methods of early detection. Far Eastern Medical Journal (Dal’nevostochnyy meditsinskiy zhurnal). 2018;2:30–35. (In Russian). https://www.elibrary.ru/item.asp?id=35259440 Accessed May 11, 2021.

26. Shumilina M.V. Kompleksnaya ul’trazvukovaya diagnostika patologii perifericheskikh sosudov. Uchebno-metodicheskoe rukovodstvo. 2nd ed. M.: NTsSSKh im. A.N. Bakuleva RAMN, 2012:384 p. (In Russian).

27. Yakubenko Yu.V. Dynamics of hemodynamic parameters in patients with chronic tension headache. Scientific Bulletin. Series “Medicine. Pharmacy” (Nauchny`e vedomosti. Seriya “Medicina. Farmaciya”). 2015;4(201):27–31. (In Russian). http://dspace.bsu.edu.ru/handle/123456789/19167 Accessed May 11, 2021.

28. Aaseth K., Grande R.B., Lundqvist C., Russell M.B. Pericranial tenderness in chronic tension-type headache: the Akershus population- based study of chronic headache. The Journal of Headache and Pain. 2014;15(1):58. https://doi.org/10.1186/1129-2377-15-58

29. Alekseev V.V. Acute musculoskeletal pain syndromes: neurological aspects of treatment. Reference book of a polyclinic doctor (Spravochnik poliklinicheskogo vracha). 2006;10:60–64. (In Russian). http://www.medlinks.ru/article.php?sid=20033 Accessed May 11, 2021.

30. Do T.P., Heldarskard G.F., Kolding L.T., Hvedstrup J., Schytz H.W. Myofascial trigger points in migraine and tension-type headache. The Journal of Headache and Pain. 2018;19(1):84. https://doi.org/10.1186/s10194-018-0913-8

31. Bendtsen L., Fernández-de-la-Peñas C. The role of muscles in tension-type headache. Current Pain and Headache Reports. 2011;15(6):451–458. https://doi.org/10.1007/s11916-011-0216-0

32. Isaak A., Ellrich J. Neuronal nitric oxide synthase is involved in the induction of nerve growth factor-induced neck muscle nociception. Headache. 2011;51(5):734–743. https://doi.org/10.1111/j.1526-4610.2011.01854.x

33. Pogoda J.M., Gross N.B., Arakaki X., Fonteh A.N., Cowan R.P., Harrington M.G. Severe Headache or Migraine History is Inversely Correlated With Dietary Sodium Intake: NHANES 1999–2004. Headache. 2016;56(4):688–698. https://doi.org/10.1111/head.12792

34. Chen L., Zhang Z., Chen W., Whelton P.K., Appel L.J. Lower Sodium Intake and Risk of Headaches: Results From the Trial of Nonpharmacologic Interventions in the Elderly. American Journal of Public Health. 2016;106(7):1270–1275. https://doi.org/10.2105/ajph.2016.303143

35. Prakash S., Kumar M., Belani P., Susvirkar A., Ahuja S. Interrelationships between chronic tension-type headache, musculoskeletal pain, and vitamin D deficiency: Is osteomalacia responsible for both headache and musculoskeletal pain? Annals of Indian Academy of Neurology. 2013;16(4):650–658. https://doi.org/10.4103/0972-2327.120487

36. Prakash S., Shah N.D. Chronic tension-type headache with vitamin D deficiency: casual or causal association? Headache. 2009;49(8):1214–1222. https://doi.org/10.1111/j.1526-4610.2009.01483.x

37. Karakulova Yu.V. Serotonergic mechanisms of tension headache. Russian Journal of Pain (Rossijskij zhurnal boli). 2013;1(38):21–22. (In Russian). https://elibrary.ru/item.asp?id=20284885 Accessed May 12, 2021.

38. Karakulova Yu.V. Serotonergic mechanisms of chronic tension headache. Russian Journal of Pain (Rossijskij zhurnal boli). 2017;1(52):9–10. (In Russian). https://elibrary.ru/item.asp?id=29160148 Accessed May 12, 2021.

39. Sokolov A.Yu., Lyubashina O.A., Amelin A.V., Panteleev S.S. The role of norepinephrine in the pathogenesis of primary headaches. Neurochemistry (Nejroximiya). 2013;30(4):289–300. (In Russian). https://doi.org/10.7868/S1027813313040092

40. Bougea A., Spantideas N., Galanis P., Katsika P., Boufidou F., Voskou P. et al. Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study. Journal of the Neurological Sciences. 2020;41(4):877–884. https://doi.org/10.1007/s10072-019-04151-4

41. Vedova C.D., Cathcart S., Dohnalek A., Lee V., Hutchinson M.R., Immink M.A., Hayball J. Peripheral interleukin-1ß levels are elevated in chronic tension-type headache patients. Pain Research and Management. 2013;18(6):301–6. https://doi.org/10.1155/2013/796161

42. Rambe A.S., Sjahrir H., Machfoed M.H. Tumour Necrosis Factor-Α, Interleukin-1 and Interleukin-6 Serum Levels and Its Correlation with Pain Severity in Chronic Tension-Type Headache Patients: Analysing Eff ect of Dexketoprofen Administration. Open Access Macedonian Journal of Medical Sciences. 2017;5(1):54–7. https://doi.org/10.3889/oamjms.2017.024

43. Olesen J. The role of nitric oxide (NO) in migraine, tensiontype headache and cluster headache. Pharmacology and Therapeutics. 2008;120(2):157–171. https://doi.org/10.1016/j.pharmthera.2008.08.003

44. Nasyrova R.F., Moskaleva P.V., Vaiman E.E., Shnayder N.A., Blatt N.L., Rizvanov A.A. Genetics factors of nitric oxid’s system in psychoneurological disorders. International Journal of Molecular Sciences. 2020;21(5):1604. https://doi.org/10.3390/ijms21051604

45. Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia. 2004;24(3):161–172. http://dx.doi.org/10.1111/j.1468-2982.2003.00644.x

46. Ashina M., Lassen L.H., Bendtsen L., Jensen R., Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial. The Lancet. 1999;353:287–289. https://doi.org/10.1016/s0140-6736(98)01079-4

47. Ashina M., Bendtsen L., Jensen R., Lassen L.H., Sakai F. Olesen J. Possible mechanisms of action of nitric oxide synthase inhibitors in chronic tension-type headache. Brain. 1999;122(9):1629–1635. https://doi.org/10.1093/brain/122.9.1629

48. Gupta R., Bhatia M.S. A report of cranial autonomic symptoms in migraineurs. Cephalalgia. 2007;27(1):22–28. https://doi.org/10.1111/j.1468-2982.2006.01237.x

49. Hamada J. Pathophysiology of migraine—migraine generator. Rinsho Shinkeigaku. 2008;48(11):857–860. https://doi.org/10.5692/clinicalneurol.48.857

50. Millan M.J. Descending control of pain. Progress in Neurobiology. 2002;66:355–474. https://doi.org/10.1016/s0301-0082(02)00009-6

51. Edvinsson L., Uddman R. Neurobiology in primary headaches. Brain Research. 2005;4(3):438–456. https://doi.org/10.1016/j.brainresrev.2004.09.007

52. Saccò M., Meschi M., Regolisti G., Detrenis S., Bianchi L., Bertorelli M. et al. The relationship between blood pressure and pain. Journal of Clinical Hypertension (Greenwich). 2013;15(8):600–605. https://doi.org/10.1111/jch.12145

53. Ghione S. Hypertension-associated hypalgesia. Evidence in experimental animals and humans, pathophysiological mechanisms, and potential clinical consequences. Journal of Hypertension. 1996;28(3):494–504. https://doi.org/10.1161/01.hyp.28.3.494

54. Coba P., Bruehl S., Garber J., Smith C.A., Walker L.S. Is Resolution of Chronic Pain Associated With Changes in Blood Pressure-related Hypoalgesia? Annals of Behavioral Medicine. 2018;52(7):552–9. https://doi.org/10.1093/abm/kax021

55. Bruehl S., Chung O.Y. Interactions between the cardiovascular and pain regulatory systems: an updated review of mechanisms and possible alterations in chronic pain. Neuroscience and Biobehavioral Reviews. 2004;28(4):395–414. https://doi.org/10.1016/j.neubiorev.2004.06.004

56. Thomsen L.L., Olesen J. Nitric oxide in primary headaches. Current Opinion in Neurology. 2001;14(3):315–321. https://doi.org/10.1097/00019052-200106000-00009

57. Sarchielli P., Alberti A., Floridi A., Gallai V. L-Arginine/nitric oxide pathway in chronic tension-type headache: relation with serotonin content and secretion and glutamate content. J. Neurological Sciences. 2002;198(1–2):9–15. https://doi.org/10.1016/s0022-510x(02)00035-7

58. Kiefer F.N., Neysari S., Humar R., Li W., Munk V.C., Battegay E.J. Hypertension and angiogenesis. Current Pharmaceutical Design 2003;9(21):1733–1744. https://doi.org/10.2174/1381612033454540

59. Hermann M., Flammer A., Lüscher T. F. Nitric oxide in hypertension. The Journal of Clinical Hypertension (Greenwich). 2006;8(12Suppl.4):17–29. https://doi.org/10.1111/j.1524-6175.2006.06032.x

60. Qiang Li, Ji-Youn Youn, Hua Cai. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. Journal of Hypertension. 2015;33(6):1128–1136 https://doi.org/10.1097/HJH.0000000000000587

61. Shinozaki K., Nishio Y., Okamura T., Yoshida Y., Maegawa H., Kojima H. et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circulation Research. 2000;87:566–573. https://doi.org/10.1161/01.res.87.7.566

62. Podjarny E., Hasdan G., Bernheim J., Rashid G., Green Ja., Korzets Z., Bernheim J. Eff ect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats, Nephrology Dialysis Transplantation, 2004;19(9):2223–2227. https://doi.org/10.1093/ndt/gfh383

63. Ihlemann N., Rask-Madsen C., Perner A., Dominguez H., Hermann T., Kober L., Torp-Pedersen C. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. American journal of physiology. Heart and circulatory physiology. 2003;285:H875–H882. https://doi.org/10.1152/ajpheart.00008.2003

64. Maier W., Cosentino F., Lutolf R.B., Fleisch M., Seiler C., Hess O.M. et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. Journal of Cardiovascular Pharmacology. 2000;35:173–178. https://doi.org/10.1097/00005344-200002000-00001

65. Hambrecht R., Hilbrich L., Erbs S., Gielen S., Fiehn E., Schoene N., Schuler G. Correction of endothelial dysfunction in chronic heart failure: additional eff ects of exercise training and oral L-arginine supplemen tation. Journal of the American College of Cardiology. 2000;35:706–713. https://doi.org/10.1016/s0735-1097(99)00602-6

66. Wang X., Michaelis E.K. Selective neuronal vulnerability to oxidative stress in the brain. Frontiers in Aging Neuroscience. 2010;2(12):1–13. https://doi.org/10.3389/fnagi.2010.00012

67. Madamanchi N.R., Vendrov A, Runge M.S. Oxidative Stress and Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;25(1):29–38. https://doi.org/10.1161/01.ATV.0000150649.39934.13

68. Kelm M., Preik M., Hafner D.J., Strauer B.E. Evidence for a multifactorial process involved in the impaired flow response to nitric oxide in hypertensive patients with endothelial dysfunction. Hypertension. 1996;27(3):346–353. https://doi.org/10.1161/01.hyp.27.3.346

69. Schlaich M.P., Parnell M.M., Ahlers B.A., Finch S., Marshall T., Zhang W.Z., Kaye D.M. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004;110(24):3680–3686. http://dx.doi.org/10.15829/1728-8800-2019-6-62-68

70. Tandai-Hiruma M., Kato K., Kemuriyama T., Ohta H., Tashiro A., Hagisawa K., Nishida Y. High blood pressure enhances brain stem neuronal nitric oxide synthase activity in Dahl salt-sensitive rats. Clinical and Experimental Pharmacology and Physiology. 2013;40(3):197–204. http://dx.doi.org/10.1111/1440-1681.12049

71. Luiking Y.C., Ten Have G.A., Wolfe R.R., Deutz N.E. Arginine de novo and nitric oxide production in disease states. Am. J. Physiol. Endocrinol. Metab. 2012;303(10):E1177–E1189. https://doi.org/10.1152/ajpendo.00284.2012

72. Ventura-Martínez R., Déciga-Campos M., Díaz-Reval M.I., González-Trujano M.E., López-Muñoz F.J. Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacininduced antinociception in rat. European Journal of Pharmacology. 2004;503(1–3):43–48. https://doi.org/10.1016/j.ejphar.2004.09.018

73. Ortiz M.I., Torres-López J.E., Castañeda-Hernández G., Rosas R., Vidal-Cantú G.C., Granados-Soto V. Role of the nitric oxide-cyclic GMP-K + channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac. Proceedings of the Western Pharmacology Society. 2002;45:174–177. https://pubmed.ncbi.nlm.nih.gov/12434573/

74. Lázaro-Ibáñez G.G., Torres-López J.E., Granados-Soto V. Participation of the nitric oxide-cyclic GMP-ATP-sensitive K(+ ) channel pathway in the antinociceptive action of ketorolac. European Journal of Pharmacology. 2001;426(1–2):39–44. https://doi.org/10.1016/s0014-2999(01)01206-7

75. Islas-Cadena M., Aguirre-Bañuelos P., Granados-Soto V. Evidence for the participation of the nitric oxidecyclic GMP pathway in the antinociceptive effect of nimesulide. Journal of Pharmacological and Toxicological Methods. 1999;42(2):87–92. https://doi.org/10.1016/s1056-8719(00)00047-2

76. Klein T., Eltze M., Grebe T., Hatzelmann A., Kömhoff M. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovascular Research. 2007;75(2):390–397. https://doi.org/10.1016/j.cardiores.2007.02.026

77. Déciga-Campos M., López-Muñoz F.J. Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception. Proceedings of the Western Pharmacology Society. 2003;46:165–167. https://www.researchgate.net/publication/8938368_Participation_of_the_NO-Cyclic_GMP_Pathway_in_Rofecoxib-Induced_Antinociception Accessed May 12, 2021.

78. Mixcoatl-Zecuatl T., Flores-Murrieta F.J., Granados-Soto V. The nitric oxide-cyclic GMP-protein kinase G-K + channel pathway participates in the antiallodynic effect of spinal gabapentin. European Journal of Pharmacology. 2006;531(1–3):87–95. https://doi.org/10.1016/j.ejphar.2005.12.006

79. Hernández-Pacheco A., Araiza-Saldaña C.I., Granados-Soto V., Mixcoatl-Zecuatl T. Possible participation of the nitric oxidecyclic GMP-protein kinase G-K + channels pathway in the peripheral antinociception of melatonin. European Journal of Pharmacology. 2008;596(1–3):70–76. https://doi.org/10.1016/j.ejphar.2008.07.068

80. Pinheiro L.C., Tanus-Santos J.E., Castro M.M. The potential of stimulating nitric oxide formation in the treatment of hypertension. Expert. Opin. Ther. Targets. 2017;21(5):543–556. https://doi.org/10.1080/14728222.2017.1310840

81. Giles T.D. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. Journal of Clinical Hypertension (Greenwich). 2006;8(12):2–16. https://doi.org/10.1111/j.1524-6175.2006.06023.x

82. Preik M., Kelm M., Feelisch M., Strauer B.E. Impaired eff ectiveness of nitric oxide-donors in resistance arteries of patients with arterial hypertension. Journal of Hypertension. 1996;14(7):903–908. https://doi.org/10.1097/00004872-199607000-00014

83. Rajapakse N.W., Giam B., Kuruppu S., Head G.A., Kaye D.M. Impaired L-arginine-nitric oxide pathway contributes to the pathogenesis of resistant hypertension. Clinical Science (Lond). 2019;133(20):2061–2067. https://doi.org/10.1042/cs20190851

84. Toblli J.E., DiGennaro F., Giani J.F., Dominici F.P. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular Health and Risk Management. 2012;8:151–160. https://doi.org/10.2147/vhrm.s20669

85. Fortepiani L.A., Ortíz M.C., Atucha N.M., García-Estañ J. Nebivolol ameliorates nitric oxide deficient hypertension. The Scientific World Journal. 2002;2:1676–1684. https://doi.org/10.1100/tsw.2002.814

86. Wegener G., Volke V. Nitric oxide synthase inhibitors as antidepressants. Pharmaceuticals (Basel). 2010;3(1):273–299. https://doi.org/10.3390/ph3010273